menu
    • menu
    [{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Alpha37","moa":"CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"APIM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Bupivacaine","moa":"PCNA\/APIM PPI","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nordic Nanovector \/ APIM Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ APIM Therapeutics"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"ICON Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ ICON Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ ICON Clinical Research"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-NNV003","moa":"||CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Nanovector

    Menu

    Nordic Nanovector

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : APIM Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Nordic Nanovector and APIM Therapeutics Announce Merger Agreement

                            Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...

                            Product Name : ATX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 11, 2022

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : APIM Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular ...

                            Details : 106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 01, 2022

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation...

                            Details : Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2...

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin in 3L R and R Follicular Lymphom...

                            Details : Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2022

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Huma...

                            Details : Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 ...

                            Product Name : Humalutin

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            March 05, 2022

                            Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b...

                            Details : The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            February 06, 2022

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Present at 3rd Targeted Radiopharmaceutical Summit 2021

                            Details : Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : ICON Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME

                            Details : Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2021

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ICON Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Ph...

                            Details : Data from this cohort is expected in H1'2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin®/40mg lilotomab.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            November 19, 2020

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to...

                            Details : The study found that Betalutin (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.

                            Product Name : Betalutin

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 10, 2020

                            Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth